Short answer
Beam Therapeutics Inc. (BEAM) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $490,000 (down 94.2% year over year) with net income of −$123M.
Q2 2026 key financials · XBRL
- Revenue
- $490,000
- −94.2% YoY · −98.5% QoQ
- Net income
- −$123M
- −19.9% YoY · −30.1% QoQ
- Operating margin
- -25827.1%
- EPS (diluted)
- −$1.18
- −19.2% YoY · −29.7% QoQ
Source: XBRL data from the Beam Therapeutics Inc. (BEAM) Q2 2026 10-Q on SEC EDGAR. USD.
Beam Therapeutics Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes identified; filing text is truncated before the formal Risk Factors section
- Regulatory risk: FDA approval for BEAM-302 depends on 12-month AAT biomarkers under an accelerated pathway
- Clinical risk: one risto-cel patient died four months post-infusion from respiratory failure likely related to busulfan conditioning
- Operational risk: pivotal BEAM-302 expansion requires approximately 50 additional patients
- Financial risk: $217.0 million six-month net loss and $1.9 billion accumulated deficit as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beam Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.